BidaskClub cut shares of Hologic (NASDAQ:HOLX) from a hold rating to a sell rating in a research report released on Thursday morning.

A number of other equities research analysts have also weighed in on HOLX. Zacks Investment Research lowered shares of Hologic from a hold rating to a sell rating in a report on Monday, April 30th. Needham & Company LLC reaffirmed a buy rating and set a $43.00 price target (down from $50.00) on shares of Hologic in a report on Tuesday, May 1st. Canaccord Genuity lowered shares of Hologic from a buy rating to a hold rating and lowered their price target for the company from $48.00 to $39.00 in a report on Thursday, May 3rd. Leerink Swann lowered shares of Hologic from an outperform rating to a market perform rating and lowered their price target for the company from $48.00 to $41.00 in a report on Thursday, May 3rd. Finally, Stifel Nicolaus lowered their price target on shares of Hologic from $42.00 to $40.00 and set a hold rating for the company in a report on Thursday, May 3rd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company’s stock. Hologic currently has a consensus rating of Hold and an average target price of $45.47.

Hologic stock opened at $38.33 on Thursday. Hologic has a 52-week low of $35.10 and a 52-week high of $45.09. The firm has a market capitalization of $11.06 billion, a PE ratio of 18.88, a price-to-earnings-growth ratio of 1.85 and a beta of 0.74. The company has a quick ratio of 0.99, a current ratio of 1.29 and a debt-to-equity ratio of 1.12.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Tuesday, July 31st. The medical equipment provider reported $0.58 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.02. The business had revenue of $824.00 million during the quarter, compared to analyst estimates of $800.14 million. Hologic had a negative net margin of 2.47% and a positive return on equity of 22.18%. research analysts anticipate that Hologic will post 2.24 EPS for the current fiscal year.

In other Hologic news, insider Peter J. Valenti III sold 10,107 shares of the stock in a transaction on Tuesday, May 29th. The shares were sold at an average price of $38.52, for a total transaction of $389,321.64. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.88% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of HOLX. Piedmont Investment Advisors LLC bought a new position in Hologic during the 2nd quarter valued at $127,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Hologic during the 1st quarter valued at $146,000. Amussen Hunsaker Associates LLC bought a new position in Hologic during the 2nd quarter valued at $159,000. Synovus Financial Corp bought a new position in Hologic during the 1st quarter valued at $164,000. Finally, Homrich & Berg bought a new position in Hologic during the 2nd quarter valued at $204,000. Hedge funds and other institutional investors own 93.34% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Further Reading: Marijuana Stocks

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.